Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Serum Electrolyte Levels in Patients with Type 2 Diabetes: A Pairwise and Network Meta-Analysis of Randomized Controlled Trials-Reference-Cited by-同舟云学术

Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Serum Electrolyte Levels in Patients with Type 2 Diabetes: A Pairwise and Network Meta-Analysis of Randomized Controlled Trials

Published:2022-03-31 Issue:3 Volume:3 Page:477-487
ISSN:2641-7650
Container-title:Kidney360
language:en
Short-container-title:Kidney360

Author:

Zhang Jingjing,Huan Yonghong,Leibensperger Mark,Seo Bojung,Song Yiqing

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference69 articles.

1. SGLT2 inhibition in diabetes mellitus: Rationale and clinical prospects;Ferrannini;Nat Rev Endocrinol,2012

2. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2016

3. Dapagliflozin and cardiovascular outcomes in type 2 diabetes;Wiviott;N Engl J Med,2019

4. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy;Perkovic;N Engl J Med,2019

5. Dapagliflozin in patients with chronic kidney disease;Heerspink;N Engl J Med,2020

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. State-of-the-Art-Review: Mechanisms of Action of SGLT2 Inhibitors and Clinical Implications;American Journal of Hypertension;2024-07-17

2. Sodium–Glucose Cotransporter Inhibitors: Cellular Mechanisms Involved in the Lipid Metabolism and the Treatment of Chronic Kidney Disease Associated with Metabolic Syndrome;Antioxidants;2024-06-26

3. Sodium/Glucose Cotransporter 2 Inhibitors and Magnesium Homeostasis: A Review;American Journal of Kidney Diseases;2024-05

4. Exploring nontraditional cardiorenal advantages of SGLT-2 inhibitors and GLP-1 receptor agonists;Kidney International;2024-03

5. SGLT2 inhibitors in peritoneal dialysis: a promising frontier toward improved patient outcomes;Renal Replacement Therapy;2024-01-31